HOME >> BIOLOGY >> NEWS
Taking the next step toward growing our own fuel

URBANA -- Developing a petroleum-free fuel from corn byproducts is one of the goals of a newly named research theme at the University of Illinois at Urbana-Champaign. Eight research laboratories will pool their expertise, attacking the problems from different directions to improve the efficiency of bioconversion of plant fibers into fuels and other value added products.

The new theme is the seventh to be chosen for the Institute for Genomic Biology under the direction of Harris A. Lewin, Gutgsell Endowed Chair in the department of animal sciences. Although the building housing the IGB will not be completed until 2006, the work that will go on inside already has begun.

Lewin said that the new IGB research theme, led by Hans Blaschek, will address one of the most critical problems facing our nation.

"With crude oil at $50 per barrel, we must examine renewal sources of energy as a viable alternative to fossil fuels," Lewin said. "The vision and experience of Blaschek and his co-workers will be important in setting the national agenda for future research on renewable energy sources. Importantly, the outcomes of this research may have direct benefit to farmers and the agricultural industries of the Midwest. I am proud to have the new theme on Molecular Bioengineering of Biomass Conversion as part of the IGB's research, education and economic development portfolio."

Blaschek is a microbiologist in the College of Agricultural, Consumer and Environmental Sciences. He has been studying microorganisms that are used in fermentation processes for over 20 years. He is striving to overcome the obstacles related to biomass conversion into value-added products.

"The beneficiaries of this research will be agriculture and agriculture-based industries in Illinois," Blaschek said, "but ultimately all of us will benefit as consumers of energy." He believes that renewable fuel made from corn is the direction we need to go in order
'"/>

Contact: Debra Levey Larson
dlarson@uiuc.edu
217-244-2880
University of Illinois at Urbana-Champaign
7-Oct-2004


Page: 1 2

Related biology news :

1. Taking a supplement of glycine helps prevent degenerative diseases such as arthrosis or osteoporosis
2. Taking heart failure to the MAT1
3. Taking chips to the next level of gene hunting
4. Vax and Pax: Taking turns to build an eye
5. Taking evolutions temperature: Researchers pinpoint the energy it takes to make a species
6. Taking a bite out of a fellow worker helps wasps recruit new foragers
7. Taking a break from fractures: A closer look at vitamin D
8. Taking a flying jump
9. Taking the piste out of Alpine vegetation
10. Bursts of waves drive immune system soldiers toward invaders
11. A decisive step toward a cure for insulin dependent diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Taking the next step toward growing our own fuel

(Date:5/19/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Genetic Testing Market Outlook 2018 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Veolia’s ... an exclusive North American distribution agreement with VWR ... system. , With more than 160 years of ... and services for laboratory and production facilities, has ... excellence and differentiated services to enable science. ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 This year ... especially for lawns. US Patented Pearl’s Premium Ultra ... lawns around the country that are coming out of ... addresses a number of major global concerns related to ... “non-grass” grass – the alternative to the standard, water-wasting, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
Cached News: